消化器疾患治療薬市場：流通チャネル、投与経路、用途別-2025-2030年の世界予測

消化器疾患治療薬市場は、2023年に401億8,000万米ドルと評価され、2024年には418億2,000万米ドルに達すると予測され、CAGR 4.00%で成長し、2030年には529億1,000万米ドルに達すると予測されています。

消化器疾患治療薬市場は、炎症性腸疾患、過敏性腸症候群、クローン病、胃食道逆流症を含むがこれらに限定されない、消化器系の疾患をターゲットとした治療ソリューションの開拓、生産、流通を包含します。この市場は、食生活の乱れ、座りっぱなしのライフスタイル、高齢化などの要因から、世界的に消化器系疾患の有病率が上昇しているため、不可欠なものとなっています。治療用途には、生物製剤、低分子製剤、酸中和剤、酵素補充剤などがあり、病院、診療所、専門医療センターなど多様なエンドユーザーにサービスを提供しています。市場は、バイオテクノロジーの急速な進歩、個別化医療に対する需要の増加、革新的治療の強力なパイプラインの影響を受けています。バイオシミラーの開発、微生物ベースの治療法の探求、ヘルスケア・インフラが改善しつつある新興国市場への進出などがチャンスです。腸と脳の相互作用を標的とする神経調節薬などの新しい治療領域は、技術革新の有望なフロンティアです。しかし市場は、医薬品開発に伴う高コスト、厳しい規制要件、ジェネリック医薬品メーカーからの競争圧力などの課題に直面しています。さらに、複雑な治療レジメンと潜在的な副作用のために、患者のアドヒアランスが依然として懸念されています。このような課題を克服するために、企業は研究開発のための戦略的パートナーシップの構築、患者エンゲージメントを向上させるためのデジタルヘルス技術への投資、リアルワールドエビデンスを用いた臨床試験の効率化に注力すべきです。イノベーションの重要な分野は、人工知能と機械学習を統合して創薬を加速し、診断能力を向上させることにあります。市場情勢はダイナミックで、規制状況も変動し、患者のニーズも進化しているため、機敏な戦略と継続的な研究開発を重視する必要があります。これらのアプローチに注力することで、企業は市場での地位を高め、消化器疾患との世界の闘いに貢献することができます。

市場力学：急速に進化する消化器疾患治療薬市場の主要市場インサイトを公開

消化器疾患治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 胃腸疾患の有病率の増加
  • セルフメディケーションと再生医療への需要の高まり
  • 消化器疾患の治療における生物製剤の採用増加
• 市場抑制要因
  • 消化器疾患に伴う社会経済的負担の増加
• 市場機会
  • 製薬企業による研究開発投資の増加
  • 消化器疾患の予防と治療に対する政府の取り組み
• 市場の課題
  • 特許切れの増加

ポーターのファイブフォース：消化器疾患治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：消化器疾患治療薬市場における外部からの影響の把握

外部マクロ環境要因は、消化器疾患治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析消化器疾患治療薬市場における競合情勢の把握

消化器疾患治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス消化器疾患治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、消化器疾患治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨消化器疾患治療薬市場における成功への道筋を描く

消化器疾患治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 消化器疾患の罹患率の増加
    • 自己治療と再生医療の需要の高まり
    • 消化器疾患の治療における生物学的製剤の採用増加
  • 抑制要因
    • 消化器疾患に関連する社会経済的負担の増大
  • 機会
    • 製薬会社による研究開発への投資増加
    • 消化器疾患の予防と治療に向けた政府の取り組み
  • 課題
    • 特許失効の増加
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 消化器疾患治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第7章 消化器疾患治療薬市場：投与経路別

• 静脈内
• オーラル

第8章 消化器疾患治療薬市場：用途別

• クローン病
• 胃食道逆流症
• 潰瘍性大腸炎

第9章 南北アメリカの消化器疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の消化器疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの消化器疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• Eisai Co. Ltd.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
• Novartis AG
• Olympus Corporation
• Ovesco Endoscopy AG
• Takeda Pharmaceutical Company Limited
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Gastrointestinal Diseases Therapeutics Market was valued at USD 40.18 billion in 2023, expected to reach USD 41.82 billion in 2024, and is projected to grow at a CAGR of 4.00%, to USD 52.91 billion by 2030.

The gastrointestinal diseases therapeutics market encompasses the development, production, and distribution of therapeutic solutions targeting ailments of the digestive system, including but not limited to inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, and gastroesophageal reflux disease. This market is indispensable due to the rising prevalence of digestive disorders globally, attributed to factors such as poor dietary habits, sedentary lifestyles, and a growing aging population. Therapeutic applications include biologics, small molecules, acid neutralizers, and enzyme replacements, serving diverse end-users like hospitals, clinics, and specialized care centers. The market is influenced by rapid advancements in biotechnology, increasing demand for personalized medicine, and a strong pipeline of innovative treatments. Opportunities lie in the development of biosimilars, the exploration of microbiome-based therapies, and the expansion into emerging markets where healthcare infrastructure is improving. New therapeutic areas, such as neuromodulators targeting gut-brain interactions, represent a promising frontier for innovation. However, the market faces challenges, including high costs associated with drug development, stringent regulatory requirements, and competitive pressure from generic drug manufacturers. Additionally, patient adherence remains a concern due to complex treatment regimens and potential side effects. To navigate these challenges, companies should focus on building strategic partnerships for research and development, investing in digital health technologies to improve patient engagement, and streamlining clinical trials using real-world evidence. A significant area for innovation lies in integrating artificial intelligence and machine learning to accelerate drug discovery and improve diagnostic capabilities. The market is dynamic, with fluctuating regulatory landscapes and evolving patient needs, necessitating agile strategies and an emphasis on continuous research and development. By focusing on these approaches, companies can enhance their market position and contribute to the global fight against gastrointestinal ailments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Diseases Therapeutics Market

The Gastrointestinal Diseases Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of gastrointestinal diseases
  • Rising demand for self-medication and regenerative medicines
  • Increasing adoption of biologics for treatment of gastrointestinal diseases
• Market Restraints
  • Rising socio-economic burden associated with GI disorders
• Market Opportunities
  • Rising investments in R&D by pharmaceutical companies
  • Government initiatives to prevent and treat gastrointestinal diseases
• Market Challenges
  • Increasing number of patent expirations

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Diseases Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Diseases Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Diseases Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Diseases Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Diseases Therapeutics Market

A detailed market share analysis in the Gastrointestinal Diseases Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Diseases Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Diseases Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Diseases Therapeutics Market

A strategic analysis of the Gastrointestinal Diseases Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Novartis AG, Olympus Corporation, Ovesco Endoscopy AG, Takeda Pharmaceutical Company Limited, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on Application, market is studied across Crohn's Disease, Gastroesophageal Reflux Disease, and Ulcerative Colitis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of gastrointestinal diseases
    • 5.1.1.2. Rising demand for self-medication and regenerative medicines
    • 5.1.1.3. Increasing adoption of biologics for treatment of gastrointestinal diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Rising socio-economic burden associated with GI disorders
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising investments in R&D by pharmaceutical companies
    • 5.1.3.2. Government initiatives to prevent and treat gastrointestinal diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Increasing number of patent expirations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

• 6.1. Introduction
• 6.2. Hospital Pharmacies
• 6.3. Online Pharmacies
• 6.4. Retail Pharmacies

7. Gastrointestinal Diseases Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral

8. Gastrointestinal Diseases Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Crohn's Disease
• 8.3. Gastroesophageal Reflux Disease
• 8.4. Ulcerative Colitis

9. Americas Gastrointestinal Diseases Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastrointestinal Diseases Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastrointestinal Diseases Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. Biogen Inc.
• 5. Boehringer Ingelheim International GmbH
• 6. Cipla Inc.
• 7. Eisai Co. Ltd.
• 8. Eli Lilly and Company
• 9. GlaxoSmithKline PLC
• 10. Johnson & Johnson Services Inc.
• 11. Novartis AG
• 12. Olympus Corporation
• 13. Ovesco Endoscopy AG
• 14. Takeda Pharmaceutical Company Limited
• 15. UCB S.A.